Acadia Pharmaceuticals Inc. announced in a press release that the FDA has rejected its application for Nuplazid to treat Alzheimer’s disease psychosis.
The Psychopharmacologic Drugs Advisory Committee (PDAC) voted nine to three that evidence presented did not support a conclusion that Nuplazid (pimavanserin, Acadia) is effective for the treatment of hallucinations and delusions in those with Alzheimer’s.
“We are disappointed with the outcome of today’s vote,” Acadia CEO Steve Davis said in the release. “We continue to believe there is substantial evidence